Dataset Information

Estimating detectability index in vivo: development and validation of an automated methodology.

ABSTRACT: This study's purpose was to develop and validate a method to estimate patient-specific detectability indices directly from patients' CT images (i.e., in vivo). The method extracts noise power spectrum (NPS) and modulation transfer function (MTF) resolution properties from each patient's CT series based on previously validated techniques. These are combined with a reference task function (10-mm disk lesion with [Formula: see text] HU contrast) to estimate detectability indices for a nonprewhitening matched filter observer model. This method was applied to CT data from a previous study in which diagnostic performance of 16 readers was measured for the task of detecting subtle, hypoattenuating liver lesions ([Formula: see text]), using a two-alternative-forced-choice (2AFC) method, over six dose levels and two reconstruction algorithms. In vivo detectability indices were estimated and compared to the human readers' binary 2AFC outcomes using a generalized linear mixed-effects statistical model. The results of this modeling showed that the in vivo detectability indices were strongly related to 2AFC outcomes ([Formula: see text]). Linear comparison between human-detection accuracy and model-predicted detection accuracy (for like conditions) resulted in Pearson and Spearman correlation coefficients exceeding 0.84. These results suggest the potential utility of using in vivo estimates of a detectability index for an automated image quality tracking system that could be implemented clinically.

SUBMITTER: Smith TB

PROVIDER: S-EPMC5724743 | biostudies-other | 2018 Jul

REPOSITORIES: biostudies-other

ACCESS DATA

Publications

Estimating detectability index <i>in vivo</i>: development and validation of an automated methodology.

Smith Taylor Brunton TB Solomon Justin J Samei Ehsan E

Journal of medical imaging (Bellingham, Wash.) 20171211 3

This study's purpose was to develop and validate a method to estimate patient-specific detectability indices directly from patients' CT images (i.e., <i>in vivo</i>). The method extracts noise power spectrum (NPS) and modulation transfer function (MTF) resolution properties from each patient's CT series based on previously validated techniques. These are combined with a reference task function (10-mm disk lesion with [Formula: see text] HU contrast) to estimate detectability indices for a nonpre ...[more]

PMID: 29250570

Similar Datasets

Project description:BackgroundDifferentiating progressive supranuclear palsy-parkinsonism (PSP-P) from Parkinson's disease (PD) is clinically challenging.ObjectiveThis study aimed to develop an automated Magnetic Resonance Parkinsonism Index 2.0 (MRPI 2.0) algorithm to distinguish PSP-P from PD and to validate its diagnostic performance in two large independent cohorts.MethodsWe enrolled 676 participants: a training cohort (n = 346; 43 PSP-P, 194 PD, and 109 control subjects) from our center and an independent testing cohort (n = 330; 62 PSP-P, 171 PD, and 97 control subjects) from an international research group. We developed a new in-house algorithm for MRPI 2.0 calculation and assessed its performance in distinguishing PSP-P from PD and control subjects in both cohorts using receiver operating characteristic curves.ResultsThe automated MRPI 2.0 showed excellent performance in differentiating patients with PSP-P from patients with PD and control subjects both in the training cohort (area under the receiver operating characteristic curve [AUC] = 0.93 [95% confidence interval, 0.89-0.98] and AUC = 0.97 [0.93-1.00], respectively) and in the international testing cohort (PSP-P versus PD, AUC = 0.92 [0.87-0.97]; PSP-P versus controls, AUC = 0.94 [0.90-0.98]), suggesting the generalizability of the results. The automated MRPI 2.0 also accurately distinguished between PSP-P and PD in the early stage of the diseases (AUC = 0.91 [0.84-0.97]). A strong correlation (r = 0.91, P < 0.001) was found between automated and manual MRPI 2.0 values.ConclusionsOur study provides an automated, validated, and generalizable magnetic resonance biomarker to distinguish PSP-P from PD. The use of the automated MRPI 2.0 algorithm rather than manual measurements could be important to standardize measures in patients with PSP-P across centers, with a positive impact on multicenter studies and clinical trials involving patients from different geographic regions. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Project description:BackgroundAlthough there has been increasing interest in patient engagement, few measures are publicly available and suitable for patients with limited health literacy.ObjectiveWe sought to develop a Consumer Health Activation Index (CHAI) for use among diverse patients.MethodsExpert opinion, a systematic literature review, focus groups, and cognitive interviews with patients were used to create and revise a potential set of items. Psychometric testing guided by item response theory was then conducted among 301 English-speaking, community-dwelling adults. This included differential item functioning analyses to evaluate item performance across participant health literacy levels. To determine construct validity, CHAI scores were compared to scales measuring similar personality constructs. Associations between the CHAI and physical and mental health established predictive validity. A second study among 9,478 adults was used to confirm CHAI associations with health outcomes.ResultsExploratory factor analyses revealed a single-factor solution with a 10-item scale. The CHAI showed good internal consistency (alpha = 0.81) and moderate test-retest reliability (ICC = 0.53). Reading grade level was found to be at the 6th grade. Moderate to strong correlations were found with similar constructs (Multidimensional Health Locus of Control, r = 0.38, P < 0.001; Conscientiousness, r = 0.41, P < 0.001). Predictive validity was demonstrated through associations with functional health status measures (depression, r = -0.28, P < 0.001; anxiety, r = -0.22, P < 0.001; and physical functioning, r = 0.22, P < 0.001). In the validation sample, the CHAI was significantly associated with self-reported physical and mental health ( r = 0.31 and 0.32 respectively; both P < 0.001).ConclusionsThe CHAI appears to be a valid, reliable, and easily administered tool that can be used to assess health activation among adults, including those with limited health literacy. Future studies should test the tool in actual use and explore further applications.

Project description:Rationale & objectiveMeasurement of residual kidney function is recommended for the adjustment of the dialysis prescription, but timed urine collections are difficult and prone to errors. Equations to calculate residual kidney function from serum concentrations of endogenous filtration markers and demographic parameters would simplify monitoring of residual kidney function. However, few equations to estimate residual kidney function using serum concentrations of small solutes and low-molecular-weight proteins have been developed and externally validated.Study designStudy of diagnostic test accuracy.Setting & participants823 Chinese peritoneal dialysis (PD) patients (development cohort) and 826 PD and hemodialysis patients from the Netherlands NECOSAD study (validation cohort).Tests comparedEquations to estimate residual kidney function (estimated clearance [eCl]) using serum creatinine, urea nitrogen, cystatin C, β2-microglobulin (B2M), β-trace protein (BTP), and combinations, as well as demographic variables (age, sex, height, and weight). Equations were developed using multivariable linear regression analysis in the development cohort and then tested in the validation cohort. Equations were compared with published validated equations.OutcomesResidual kidney function measured as urinary clearance (mCl) of urea nitrogen (mClUN) and average of creatinine and urea nitrogen clearance (mClUN-cr).ResultsIn external validation, bias (difference between mCl and eCl) was within ± 1.0 unit for all equations. Accuracy (percent of differences within ± 2.0 units) was significantly better for eClBTP, eClB2M, and eClBTP-B2M than eClUN-cr for both mClUN (78%, 80%, and 81% vs 72%; P < 0.05 for all) and mClUN-cr (72%, 78%, and 79% vs 68%; P < 0.05 for all). The area under the curve for predicting mClUN > 2.0 mL/min was highest for eClB2M (0.853) and eClBTP-B2M (0.848). Results were similar for other validated equations.LimitationsDevelopment cohort only consisted of PD patients, no gold-standard method for residual kidney function measurement.ConclusionsThese results confirm the validity and extend the generalizability of residual kidney function estimating equations from serum concentrations of low-molecular-weight proteins without urine collection.

Dataset Information

Estimating detectability index in vivo: development and validation of an automated methodology.

Publications

Estimating detectability index <i>in vivo</i>: development and validation of an automated methodology.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets